MBX Biosciences reported that its once-weekly investigational hormone replacement drug canvuparatide achieved a 63% response rate in a Phase 2 trial for chronic hypoparathyroidism, outperforming placebo (31%). While this met the primary endpoint, analysts highlight the high placebo response and relatively narrower benefit compared to competitors such as Ascendis Pharma’s approved Yorvipath. Investors and clinicians will be monitoring whether MBX's candidate can establish differentiation in this rare endocrine niche market.